Project Grant R01DK140281
- This $172,232 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to understand the causes of inflammatory bowel disease (IBD) therapy failure. The principal investigator, Dr. Simon M. Gray, a gastroenterologist at the University of North Carolina at Chapel Hill, will leverage a pre-clinical mouse model to study the immunologic and...
- This $164,188 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The 5-year grant supports training and research at the University of Washington to study the role of intestinal chondroitin sulfate glycosaminoglycans in inflammatory bowel disease. The research aims to determine how changes in the composition of these gut matrix...
- This federal Project Grant award of $2,076,999 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the role of mitochondrial dysfunction in Paneth cells and its relationship to inflammatory bowel diseases, including Crohn's disease. The principal investigator will use a mouse model with Paneth cell-specific deletion of the mitochondrial chaperone protein Prohibitin 1 to...
- This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop and test a novel optical imaging technology to observe the dynamics and heterogeneity of host-microbe interactions in the live mouse intestinal microenvironment. The $1 award, made on August 6, 2025, supports the establishment of a multiphoton super-resolution microscopy method capable of label-free...
- The federal Project Grant award of $309,038, issued on August 8, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports the development of a novel anti-infective therapy for treating periodontitis. The project aims to develop a first-in-class inhibitor of the "red complex" bacteria (P. gingivalis, T. forsythia, and T. denticola) that are considered the causative agents of periodontitis, a...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate gut microbial functions that impact Crohn's disease risk. Specifically, the $235,500 award to Rutgers, The State University of New Jersey will generate shotgun metagenomic sequencing data from samples collected from multiplex Crohn's disease families....
- This federal Project Grant award of $311,000.00 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will be used by the University of Washington to conduct research to characterize the microbial and inflammatory state within distant clinically healthy tissues in patients with active periodontal disease. The research aims to increase understanding of how inflammation is triggered and maintained during the...
- This federal Project Grant award of $790,359, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop a targeted probiotic yeast therapeutic for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The research project aims to design, characterize, and optimize a fibronectin-targeting, nanobody...
- This federal Project Grant award of $228,948 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Weill Medical College of Cornell University to investigate the role of the neuropeptide adrenomedullin 2 (ADM2) in regulating intestinal inflammation and promoting tissue protection in inflammatory bowel diseases (IBD) such as ulcerative...
- This federal Project Grant award of $151,643 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by Dr. Ornelas Sanchez at the University of Colorado-Denver to investigate the use of proteolysis targeting chimeras (PROTACs) to regulate hypoxia-inducible factors (HIFs) and their potential therapeutic applications for inflammatory bowel disease (IBD)....
This federal Project Grant award of $3,340,009 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to elucidate the potential causal role of periodontitis (a prevalent oral infection) in inflammatory bowel disease (IBD). The University of Maryland, Baltimore is the primary awardee and will leverage animal models to determine if oral bacteria from IBD patients and periodontitis can colonize the intestines and promote colonic inflammation. The award will also explore the aberrant inflammatory responses activated by periodontitis and oral pathogens that mediate colonic inflammation, as well as identify the gastric acid resistance mechanisms of oral bacteria. This research is intended to improve understanding of the link between oral health and intestinal health, potentially leading to better prevention, diagnosis, and treatment of IBD, which has seen a 31% surge in global incidence between 1990 and 2017.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.3m | 8/28/25 |